Company Overview of Agency for Science, Technology and Research
Agency for Science, Technology and Research provides economic oriented research to advance scientific discovery and develop innovative technology in Singapore. The company provides research services in the areas of biomedical sciences, including cancer genetics, stem cells and regenerative medicine, infectious disease and immunology, metabolic diseases, molecular cell and development biology, biomedical engineering, and platform technologies; and physical sciences and engineering, such as computational and device technologies, materials, chemistry, mechatronics and automation, manufacturing technology, metrology, and biotechnology, as well as information, communications, and media. It also o...
1 Fusionopolis Way
#20-10 Connexis North Tower
Founded in 1990
Key Executives for Agency for Science, Technology and Research
Managing Director and Executive Director
Chief Scientist and Director of p53 Lab
Deputy Managing Director of Corporate & Legal and General Counsel
Chairman of Biomedical Research Council and Director
Executive Chairman of Exploit Technologies Pte Ltd
Compensation as of Fiscal Year 2015.
Agency for Science, Technology and Research Key Developments
Visterra Partners with Agency for Science, Technology and Research to Develop VIS513
May 21 15
Visterra, Inc. and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research, Singapore announced a collaboration to further the development of VIS513, Visterra's broadly neutralizing antibody for the treatment of dengue fever. VIS513, which was engineered using Visterra's innovative and proprietary technology, is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. The company's preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection. The collaboration combines Visterra's expertise in therapeutic antibodies for challenging infectious diseases with D3's proficiency in bringing early stage discoveries into clinical development. D3 and Visterra will also work together with infectious disease experts at Duke-National University of Singapore (Duke-NUS) to generate additional data necessary to initiate clinical trials of VIS513. Upon completion of these activities, D3 and Visterra will advance VIS513 through proof-of-concept clinical trials in humans, which will be conducted in Singapore. Under the terms of the collaboration agreement Visterra retains all rights to develop and commercialize VIS513 globally.
Agency for Science, Technology and Research Presents at FT Asia Pharma Healthcare Summit, May-20-2015 09:40 AM
Apr 16 15
Agency for Science, Technology and Research Presents at FT Asia Pharma Healthcare Summit, May-20-2015 09:40 AM. Venue: InterContinental, 80 Middle Road, Singapore, Singapore. Speakers: Benjamin Seet, Executive Director of Biomedical Research Council.
The Ministry of Trade and Industry Announces Board Appointments at A*Star, Effective April 1, 2015
Mar 31 15
The Ministry of Trade and Industry announced appointment changes at board of A*Star. A*Star will gain two members: Mr. Yee Ping Yi, Designate Deputy Secretary for Policy at the Ministry of Finance, and Ms. Tan Li San, Deputy Secretary for Industry and Information at the Ministry of Communications and Information. All appointments will take effect from April 1, 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|